Mitsubishi UFJ Trust & Banking’s Corcept Therapeutics CORT Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$706K	Buy	+8,124	New	+$491K	﹤0.01%	952

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's CORT Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 8,124 shares worth $706K. The stake represents ﹤0.01% of the portfolio and ranks #952 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 8,124 shares of Corcept Therapeutics worth $706K as of Q2 2026.
Corcept Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #952 holding.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.